Presentation is loading. Please wait.

Presentation is loading. Please wait.

E. Martinelli DVM; P. Brambilla DVM, PhD; C. Locatelli DVM, PhD; S

Similar presentations


Presentation on theme: "E. Martinelli DVM; P. Brambilla DVM, PhD; C. Locatelli DVM, PhD; S"— Presentation transcript:

1 CARDIORENAL SYNDROME IN DOGS WITH MITRAL VALVE DISEASE: A PROSPECTIVE STUDY
E. Martinelli DVM; P. Brambilla DVM, PhD; C. Locatelli DVM, PhD; S. Crosara DVM, PhD, DECVIM-CA (Cardiology); Anna Maria Zanaboni PhD; C. Quintavalla DVM, PhD. BACKGROUND: Cardiac disease is often associated with worsening renal function, in humans1,2. The cardiorenal syndromes (CRS) were defined as disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other1. Recurrent episodes of heart and/or kidney failure are considered one of the causes leading to worsening heart/renal functions2. The main marker of kidney’s disease in humans is considered the glomerular filtration rate. However, serum creatinine (sCr), urine protein:creatinine ratio (UPC) and worsening renal function (WRF - sCr elevation ≥0.3 mg/dl or 25% from baseline) are recognized as predictors of renal damage3,4. HYPOTHESIS: The aim of this prospective study was to assess the influence of heart/kidney worsening on elected parameters of heart/kidney function in dogs affected by mitral valve disease (MVD). METHODS: Between July 2012 and May 2013, dogs affected by MVD in ACVIM class B2 and without comorbidities were included in the study group. The control group was constituted by healthy dogs, matched with the cases for age (older than 6 years) and gender. Table: characteristics of the study group (dogs with MVD) and control group (healthy dogs). All the dogs underwent physical examination, thorax radiography, ECG, echocardiography, systemic blood pressure assessment, a complete blood count, serum biochemical analysis, including assessment of serum creatinine (sCr), serum urea nitrogen (UREA) and glycaemia (GLY) and urine analysis with urine protein/creatinine ratio (UPC). Dogs were re-evaluated every 6-month until October Statistical analysis was performed using IBM SPSS Statistics 20 (p value significant if <0.05). NUM AGE BW Male Female mean SD 21 CASES 12 9 11.2 2.6 16.5 20 CONTROLS 8 9.3 3.1 24.4 10.6 RESULTS: Twenty-one dogs affected by MVD (cases) were included and 20 healthy dogs (controls) were randomly selected among the eligible population. The 33% of cases experienced at least one episode of congestive heart failure (CHF), but none of these patients developed chronic kidney disease (CKD). The 14% of cases developed CKD while remaining in ACVIM class B2. No dogs in the control group developed CKD or MVD. Correlations between worsening renal function (WRF - sCr elevation ≥0.3 mg/dl or 25% from baseline), furosemide administration, UPC levels, radiographic parameters of heart enlargement and echocardiographic parameter were investigated. Only a statistically significant difference in IRIS class between the groups according to WRF and in the echocardiographic parameter left atrium to aortic root (LA/Ao) according to furosemide amount were observed. Both these results were expected. None of the cases included experienced renal damage (WRF or IRIS class change or UPC change) concomitant to episodes of CHF. Figure: follow up of 20 healty dogs (controls) Light green: normoazotemic dogs; RIP: time of death. No control dogs experienced CHF or WRF in the study period. Causes of death were all different from cardiac or renal death. Figure: follow up of 21 dogs with MVD (cases). Green: ACVIM class B2; Blue: ACVIM class C; Heart: experiencing CHF; RIP: time of death; CKD: renal death; HF: cardiac death; WRF: experiencing worsening renal function. No dogs experienced concomitant CHF and WRF. CONCLUSIONS: The persistence of normal renal condition regardless of CHF events (and viceversa) and therapy administration was unexpected. Experiencing CHF seems not to directly affect renal function. To authors’ opinion, the use of WRF, better than single sCr and UREA levels, may be useful in the long term management of aged patients affected by MVD. However, the small number of cases included in this study represents a great limit. We consider this work a pilot study. REFERENCES: 1. Ronco C, Di Lullo L. Cardiorenal syndrome. Heart Fail Clin Apr;10(2):   2. Wencker D. Acute Cardio-renal Syndrome: Progression from Congestive Heart Failure to Congestive Kidney Failure. Current Heart Failure Reports. 2007; 4: 3. Grauer GF. Proteinuria: measurement and interpretation. Top Companion Anim Med Aug;26(3):121-7. 4. Smith GL., Vaccarino V., Kosiborod M., et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J. Card. Fail 2003; 9:13-25


Download ppt "E. Martinelli DVM; P. Brambilla DVM, PhD; C. Locatelli DVM, PhD; S"

Similar presentations


Ads by Google